NRIX vs. IRON, AUPH, ALXO, SVRA, PRAX, PRTC, PHAR, ELVN, TYRA, and YMAB
Should you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Disc Medicine (IRON), Aurinia Pharmaceuticals (AUPH), ALX Oncology (ALXO), Savara (SVRA), Praxis Precision Medicines (PRAX), PureTech Health (PRTC), Pharming Group (PHAR), Enliven Therapeutics (ELVN), Tyra Biosciences (TYRA), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Disc Medicine (NASDAQ:IRON) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Disc Medicine has a net margin of 0.00% compared to Disc Medicine's net margin of -178.93%. Nurix Therapeutics' return on equity of -23.37% beat Disc Medicine's return on equity.
Disc Medicine has higher earnings, but lower revenue than Nurix Therapeutics. Disc Medicine is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Disc Medicine has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.
83.7% of Disc Medicine shares are held by institutional investors. 4.7% of Disc Medicine shares are held by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Nurix Therapeutics received 24 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 71.88% of users gave Disc Medicine an outperform vote while only 70.15% of users gave Nurix Therapeutics an outperform vote.
Disc Medicine currently has a consensus target price of $57.29, indicating a potential upside of 90.83%. Nurix Therapeutics has a consensus target price of $21.33, indicating a potential upside of 47.74%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Nurix Therapeutics.
In the previous week, Nurix Therapeutics had 7 more articles in the media than Disc Medicine. MarketBeat recorded 14 mentions for Nurix Therapeutics and 7 mentions for Disc Medicine. Nurix Therapeutics' average media sentiment score of 0.74 beat Disc Medicine's score of 0.38 indicating that Disc Medicine is being referred to more favorably in the media.
Summary
Disc Medicine beats Nurix Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Nurix Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nurix Therapeutics Competitors List
Related Companies and Tools
